First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

BACKGROUND: Bromodomain and extra-terminal domain (BET) proteins are reported to be epigenetic anti-cancer drug targets. This first-in-human study evaluated the safety, pharmacokinetics and preliminary anti-tumour activity of the BET inhibitor ODM-207 in patients with selected solid tumours. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Ameratunga, Malaka, Braña, Irene, Bono, Petri, Postel-Vinay, Sophie, Plummer, Ruth, Aspegren, John, Korjamo, Timo, Snapir, Amir, de Bono, Johann S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722752/
https://www.ncbi.nlm.nih.gov/pubmed/32989226
http://dx.doi.org/10.1038/s41416-020-01077-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722752/
https://www.ncbi.nlm.nih.gov/pubmed/32989226
http://dx.doi.org/10.1038/s41416-020-01077-z

Ejemplares similares